Overview
- Monash University published peer-reviewed results on June 15, 2026, reporting that a 56-day regimen of Cu(ATSM) in APP/PS1 transgenic mice increased P-glycoprotein (P-gp) at the blood–brain barrier by 24.1 percent.
- The treatment reduced brain amyloid‑beta levels by about 42 percent and produced roughly 44 percent improvement in long-term spatial learning in the mouse model.
- Authors propose the drug clears amyloid by restoring the P-gp efflux pump and possibly by boosting microglial uptake, but they say the exact routes by which protein leaves the brain remain to be mapped.
- Cu(ATSM) has prior clinical testing in Parkinson’s disease and ALS, which the team says could speed translational steps, yet no clinical evidence of benefit in people with Alzheimer’s has been reported.
- The study includes declared commercial ties to licensing entities, and researchers call for mechanistic work and carefully designed early symptomatic human trials before any claim of patient benefit.